Targets › POLQ
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2028.
Low-fidelity DNA polymerase with a putative helicase activity that promotes microhomology-mediated end-joining (MMEJ), an alternative non-homologous end-joining (NHEJ) machinery required to repair double-strand breaks in DNA during mitosis. MMEJ is an error-prone repair pathway that produces deletions of sequences from the strand being repaired and promotes genomic rearrangements, such as telomere fusions, some of…. (UniProt, O75417)
Open in Phaseline: the race on POLQ, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Novobiocin Sodium DNA polymerase theta inhibitor | POLQ | Phase 1 | Metastatic Malignant Solid Neoplasm | Jul 2028 |
Metastatic Malignant Solid Neoplasm (1)
protein or peptide (1)
National Cancer Institute (NCI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.